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Beta3-adrenergic receptorAdipose tissue plays an essential role in regulating energy balance through its metabolic, cellular and endocrine
functions. Adipose tissue has been historically classiﬁed into anabolic white adipose tissue and catabolic brown
adipose tissue. An explosion of new data, however, points to the remarkable heterogeneity among the cells
types that can become adipocytes, as well as the inherentmetabolic plasticity of mature cells. These data indicate
that targeting cellular and metabolic plasticity of adipose tissue might provide new avenues for treatment of
obesity-related diseases. This review will discuss the developmental origins of adipose tissue, the cellular com-
plexity of adipose tissues, and the identiﬁcation of progenitors that contribute to adipogenesis throughout devel-
opment.Wewill touch upon the pathological remodeling of adipose tissue and discuss how our understanding of
adipose tissue remodeling can uncover new therapeutic targets. This article is part of a Special Issue entitled:
Modulation of Adipose Tissue in Health and Disease.
© 2013 Published by Elsevier B.V.1. Introduction
Adipose tissue (AT) is an organ that typically functions as the body's
energy reservoir by storing energy in the form of triglyceride (TG) in
times of surfeit, and mobilizing energy in the form of fatty acids in
times of need. Because fatty acids and their metabolic products can be
toxic, homeostatic mechanisms exist to ﬁnely balance lipid storage and
mobilization to prevent accumulation of potentially toxic lipids in pe-
ripheral organs [1]. The ability of the adipose organ to buffer variations
in energy supply and demand is achieved by integrated endocrine and
metabolic responses, as well as through dynamic changes in cellular
composition [2]. The buffering capacity of adipose tissue can be exceeded
during chronic overnutrition, resulting in the spillover of lipids from fat
tissue and their pathological accumulationwithin othermajormetabolic
organs. Metabolites derived from this ectopic lipid accumulation impair
insulin action in peripheral tissues and insulin production by the pancre-
as [1,3] in a process termed lipotoxicity [1]. Thus, one might anticipate
that promoting the ability of AT to store or oxidize excess lipid energy
would have beneﬁcial effects on whole body metabolism.
White adipose tissue (WAT) can expand its energy-buffering capacity
by fat cell hypertrophy and/or by hyperplasia from committed progeni-
tors. Although AT mass is a rough predictor of diabetes risk, the amount
of fat tissue matters less than the ability of the tissue to act as an energy
buffer [3]. For example, patients with mutation of phosphatase andion of Adipose Tissue in Health
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sevier B.V.tensin homolog [4] are obese yet insulin sensitive, whereas patients
with familial partial lipodystrophy exhibit ectopic lipid accumulation
and are severely insulin resistant and diabetic [5]. Similarly, limiting AT
expansion during overnutrition in rodents promotes ectopic lipid accu-
mulation and accelerates diabetes [6], whereas expanding storage capa-
bility reduces ectopic triglyceride accumulation and improves insulin
sensitivity [7].
In contrast toWAT, brown adipose tissue (BAT) is a highly oxidative
tissue containingmultilocular fat cellswith abundantmitochondria that
oxidize fatty acids and generate heat via uncoupling protein 1 (UCP1).
Classic BAT is clearly the dominant site of nonshivering thermogenesis
in rodents [8], and there is little doubt that variations in thermoregula-
tory thermogenesis can contribute greatly to disturbances in energy
balance [9].Whether classic BAT is important for energy balance during
nutritional challenges continues to be amatter of debate [10–12]. How-
ever, the recent identiﬁcation of BAT in humans [13] raises the possibil-
ity that pharmacological activation of BAT might combat obesity and
improve insulin action [14], as it clearly does in rodents [15].
WAT has been historically deﬁned by anatomical location and the
presence of parenchymal cells containing a single large lipid droplet
and sparsemitochondria lacking UCP1. However,WAT can be remodeled
under various physiological and pharmacological conditions to a more
oxidative phenotype resembling that of BAT, including the presence of
multilocular cells that are rich inmitochondria containing UCP1. This cat-
abolic remodeling is prominent in rodents and can be brought about by
activating adipocyte receptors such as β3-adrenergic receptors (β3-AR)
and peroxisome proliferator-activated receptor γ (PPARγ). Importantly,
activation of BAT, and possibly brown adipocytes (BA) in WAT [16], can
have anti-obesity effects and improve glucose homeostasis in rodent
models of type 2 diabetes [15]. Recent observations indicating that BA
in human supraclavicular BAT resemble those that can be recruited in
Table 1





















PPARγ Adipogenic WAT (retroperitoneal,
inguinal)
[52]
SM22 Vascular smooth muscle
cells (VSMC)
Perivascular adipose tissue [36]
[37]
Sox10 Neural crest Facial WAT (salivary gland
and ear)
[34]
VE-cadherin Endothelial cells WAT and BAT [61]
[65]
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beneﬁt in man [17,18].
Work in experimental models has demonstrated the remarkable
plasticity of the adipose organ [19], and it is clear that beneﬁcial effects
can be achieved by promoting either anabolic or catabolic phenotypes.
If modulation of adipocyte phenotypes is to be realized as a therapeutic
approach, then it becomes essential to develop a better understanding
of the cell types and extrinsic signals that contribute to AT development
and plasticity. In this review, we discuss the origin of AT, including a
historic description of AT ontogeny and the current understanding of
adipocyte progenitors. We examine depot-speciﬁc heterogeneity in
the origin and transcriptional requirements of adipogenesis, and intro-
duce the concept of an adipogenic tissue niche that involves cellular and
matrix components. Finally, we discuss AT plasticity and how targeting
adipocyte receptors can be used to improve AT function.
2. Development of adipose tissue
Adipogenesis is a highly ordered process that is initiated during
development and continues throughout life [20]. Seminal histological
experiments conducted in the 1960s deﬁned the ontogeny of AT and
provided a foundation for delineating adipocyte progenitors usingmod-
ern genetic tracing techniques [21,22]. In brief, AT organogenesis can be
divided into distinct stages, which are characterized by cellular compo-
sition and differentiation status. Presumptive AT ﬁrst appears as loose
connective tissues which contain extracellular matrix with sparse,
mostly mesenchymal, cells [21]. These unvascularized “prestructural
territories” appear to provide a framework for further recruitment of
progenitors and subsequent adipogenesis [22]. Over time, mesenchy-
mal cells aggregate to form “mesenchymal lobules,”which have a retic-
ular structure [21]. Major events of this stage include vascularization
and expansion of mesenchymal cells [23–25]. Proliferation kinetic stud-
ies in rodents have shown that mitoses are mostly found in poorly dif-
ferentiated mesenchymal cells that subsequently differentiate into
adipocytes [26,27]. Differentiating progenitors accumulate micro-lipid
droplets to form “primitive fat lobules” [22,28]. Adipogenesis appears
to be guided in a central to peripheral gradient by the developing capil-
lary networks that bud from the central vasculature [22]. Eventually,
the primitive AT matures to form “deﬁnitive fat lobules” that are
enclosed by connective tissue septae [23,29]. Finally, terminal differen-
tiation and enlargement of individual adipocytes occur, which are the
major modes of postnatal AT growth [30].
The developmental timing of adipogenesis differs among species, and
varies by anatomical location. AT development is initiated during the
second trimester in humans [23,24,29], and during the perinatal period
in rodents [27,31]. Subcutaneous AT generally develops before abdomi-
nal adipose tissue in rodents [26,27] and humans [32]. Overall, differen-
tiation progresses in an anterior to posterior, rostral to caudal, and dorsal
to ventral direction in various species, including man [25,28]. BAT de-
velops before WAT, and can easily be identiﬁed at birth in most mam-
mals [33]. BAT histogenesis resembles that of WAT, but has slightly
denser andmore compact reticular structures during primitive fat lobule
formation [22].
3. Adipocyte progenitors
Application of the stem cell concept to AT biology launched an explo-
sion of research into the molecular characteristics and differentiation
potential of progenitor cells that reside in AT. Although the precise iden-
tity of adipocyte progenitors in humans remains unknown, modern ap-
proaches, including in vivo lineage tracing and FACS-based prospective
analyses, have enabled extensive characterization of adipocyte progeni-
tors in mouse models. As discussed below, growing evidence suggests
that several cell types can give rise to adipocytes in vivo, depending on
developmental stage, anatomic location, and physiological conditions.3.1. Adipocyte progenitors during development
Based on earlier histogenetic studies, a mesodermal origin of AT has
beenwidely accepted. However, the fact that AT depots appear at differ-
ent times and possess distinct molecular characteristics suggests that
there may be regional heterogeneity among AT depots. In addition,
genetic lineage tracing using Cre-LoxP recombination has shown di-
verse developmental origins of AT (Table 1). For example, lineage trac-
ingwith amarker of neural crest (Sox10) demonstrated that adipocytes
in the head and neck are generated from the neuroectoderm, rather
than the mesoderm [34]. Interestingly, the bones and muscles of the
skull and face also appear to be of neural crest origin [35], suggesting
that local mesenchymal lineages have a common origin in a given ana-
tomic location. Similarly, lineage tracing showed that SM22-Cre, which
is active in vascular smoothmuscle cells (VSMC) and surroundingmes-
enchyme, marks perivascular adipose tissue (PVAT), indicating a close
lineage relationship between PVAT and VSMC [36,37].
Notably, in vivo fate-mapping and lineage-tracing studies have
established that cells expressing the early myogenic factor Myf5 can
give rise to both skeletal myocytes and BA in the interscapular and
perirenal BAT depots [38,39]. Moreover, the BA that emerge in WAT in
response to β3-AR stimulation or cold stress are not tagged by Myf5-
Cre, indicating that the origins of classic BA (which reside in BAT) and
inducible BA in WAT are distinct [39]. Because the Myf5 promoter is
transiently activated in undifferentiated paraxial mesoderm, cells with
a history of Myf5 expression give rise to multiple types of cells, includ-
ing cartilage and bone [40]. In this regard, recent ﬁndings demonstrate
that adipocytes derived from Myf5-expressing progenitors are hetero-
geneously expressedwithin a givenWAT depot [41]. Asmentioned ear-
lier, AT depots develop over time in a rostral to caudal direction [20,42].
Conditional deletion of PTEN in Myf5+ expressing cells speciﬁcally in-
creases adiposity in the upper body [41], implying earlier developmen-
tal timing of Myf5+ cell-derived adipocytes. It is not clear, however,
whether Myf5 is an important determinant of adipogenesis or whether
tagging by Myf5-Cre reﬂects transient expression within undifferentiat-
ed paraxial mesoderm. Although constitutive Cre-LoxP systems have
provided deﬁnitive evidence of the contribution of speciﬁc lineages to
AT, use of inducible reporter systems is required to deﬁne the timing of
lineage speciﬁcation. In this regard, lineage tracing with an inducible
Pax7reporter demonstrated that the developmental divergence be-
tween BAT and muscle occurs around E10.5 to E12.5 [43].
Gene knockout studies in mice indicate that the transcriptional pro-
gram controlling adipogenesis varies among fat depots. For example,
genetic ablation of CEBPα impairs development of subcutaneous and
gonadal WAT, whereas mammary WAT and interscapular BAT are
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in interscapular BAT formation, whereas WAT is relatively unaffected
[45]. Conversely, fat-speciﬁc inactivation of canonical hedgehog signal-
ing causes loss of WAT, but not BAT [46]. In humans, inherited partial
lipodystrophies often do not appear until adolescence, and then affect
certain fat depots (e.g., subcutaneous WAT) and not others [47–49].
Together, these observations support a theory of inter-depot heterogene-
ity in developmental origin and transcriptional control of adipogenesis.
Despite variations in molecular signatures of adipocyte progenitors
among individual depots [50,51], it is widely agreed that PPARγ is the
requisite master regulator for differentiation of committed progenitors
into adipocytes in all AT depots. Utilizing inducible PPARγ reporter
strains, Tang et al. identiﬁed a population of committed progenitors
that give rise to adipocytes during perinatal expansion of inguinal and
retroperitoneal WAT [52]. Commitment, as deduced from reporter
gene expression, occurs prenatally and the progenitors undergo dra-
matic postnatal expansion. Surprisingly, the PPARγ gene was active,
as indicated by reporter gene expression, yet known PPARγ targets
(e.g., CEBPα, fatty acid binding protein 4, leptin) were not expressed.
This may reﬂect the sensitivity of the reporter system to very low levels
of PPARγ that are found in pre-adipocytes, or the absence of mediators
that initiate PPARγ activity of quiescent preadipocytes. Interestingly,
many of these committed preadipocytes in this study had a perivascular
location and expressed pericyte markers.
3.2. Adipocyte progenitors in adult adipose tissue
3.2.1. Mesenchymal stem cells
Mesenchymal stem cells (MSC) are postnatal progenitorswithmulti-
ple lineage potential and can be found in adipose tissue, bone marrow,
and other connective tissues [53]. MSC that reside in adipose tissue are
generally believed to be a principal source for adipocytes during postna-
tal growth and maintenance of adipose tissue [54]. Numerous studies
have isolated subpopulations of SVC and identiﬁed reliable cell surface
markers that can be used to enrich highly adipogenic subpopulations
(see review [54]). Among those studies, Rodeheffer et al. identiﬁed
Lin-CD29+CD34+Sca-1+CD24+ cells (CD24+ cells) as cells that
can reconstitute a functional epididymal fat pad when transplanted
into lipodystrophic mice [55]. CD24+ cells are relatively rare (0.08% of
SVC), yet have a remarkable capacity for self-renewal and can form a
functional organ with a limited number of cells. In subsequent studies,
these investigators conﬁrmed that all adipocyte progenitors express
platelet-derived growth factor receptor alpha (PDGFRα) [56], and
these cells can be further subdivided into CD24+ and CD24− fractions.
CD24 expression in PDGFRα cells appears to reﬂect the state of
adipogenic commitment, since CD24− PDGFRα cells are unable to form
functional WAT in the adipogenic environment of a lipodystrophic
mouse, yet do give rise to adipocytes at an ectopic site after transplanta-
tion. The PDGFRα+CD24− cells observed by the Rodeheffer [57] and
Granneman labs [56] appear to be highly similar, if not identical, popula-
tion of lineage-committed progenitors. This indicates that CD24+ cells
may be early-stage stem cells (i.e., long-term reconstituting stem
cells), and can give rise to lineage restricted adipogenic progenitors
(i.e., short-term reconstituting stem cells). In line with this observation,
subpopulations ofMSC in adult adipose tissue have been reported to ex-
press the multipotency markers OCT4 and telomerase [58]. Additional
studies, such as global transcriptome analysis of the CD24+ and
CD24− populations might identify additional markers of adipose
stem cells. Long-term reconstituting stem cells in other tissues often oc-
cupy a specialized niche that is important for ensuring stemness. How-
ever, it is presently unknownwhether such a specialized stem cell niche
exists within AT.
Although immunotyping studies have identiﬁed potential adipocyte
progenitor markers, genetic or chemical tracing is required to demon-
strate lineage potential in vivo [59]. Taking advantage of inducible
Cre-LoxP technology, we have identiﬁed cells in WAT that are capableof becoming BA or WA, depending on inductive signals [56]. These
cells express the surface markers CD34+Sca1+ PDGFRα+ cells
(PDGFRα+cells) and have a unique dendritic morphology. Although
these cells are often found in the perivascular region, they are negative
for pericyte markers and thus are distinct from developmental adipo-
cyte progenitors. The morphology, localization, and immunophenotypes
of PDGFRα+ cells are strikingly similar to adipogenic CD34+ cells in
human adipose, which also do not express pericyte markers [60]. Inter-
estingly, PDGFRα+ cells isolated from various depots exhibit similar
adipogenic behavior in vitro, yet PDGFRα+ cells in gonadal WAT are
much more prone to be activated by β3-AR stimulation and high fat
diet (HFD). These observations suggest that extrinsic cues from the AT
microenvironments might be important in depot-speciﬁc progenitor
recruitment in vivo.
3.2.2. Endothelial origin
The close temporal–spatial association between angiogenesis and
adipogenesis suggests that adipocytes may have endothelial origins;
however, whether adipocytes arise from the endothelium or its under-
lying mesenchyme has long been a matter of debate. Recent lineage
tracing of VE-cadherin expressing cells [61] suggests a contribution of
endothelial lineages to WA and BA. In addition, the endothelial cells
expressed a preadipocyte determination marker, ZFP432 [62], although
ZFP432 is expressed in numerous cell types. Adipocytes derived from
VE-cadherin+ progenitors may represent a subpopulation, as they do
not appear to be uniformly distributed throughoutWAT pads. In this re-
gard, committed endothelial cells (CD31+CD34+) from dissociated
AT are not adipogenic in vitro [63,64], and the original characterization
of VE-cadherin Cre mouse model showed little, if any, contribution of
these progenitors toWAT [65]. This discrepancymay be due to the tech-
nical difﬁculty of discriminating adipocytes from surrounding endothelial
cells, particularly when the lacZ reaction product is used as a reporter. To
address controversies, a recent study used amembrane-targeted ﬂuores-
cent reporter line, and demonstrated that endothelial cells, marked by
either Cdh5 (VE-cadherin) or Tie2 promoter activation, do not contribute
to adipogenesis during normal development and HFD feeding [57].
Alternatively, MSC in adipose tissue could be common progenitors for
endothelial cells and adipocytes, as SVC can differentiate into endothe-
lial cells in vitro [66,67] and in vivo [68].
3.2.3. BM-derived hematopoietic progenitors
Several studies indicate that circulating hematopoietic progenitors
derived from bone marrow (BM) can participate in adipogenesis
[69–71]. Genetic lineage tracingwith LysM-Cre indicates that adipogenic
progenitors are derived from the myeloid lineage [69] and BM-derived
progenitors contribute to adipogenesis in a sex- and depot-speciﬁc fash-
ion [72]. However, transplantation experiments [73] and genetic
tracing with Tie2 and Vav1-reporter lines failed to conﬁrm a hemato-
poietic contribution to adipogenesis during normal development
and high fat feeding [57]. Nonetheless, compared to conventional
adipocytes, BM-derived adipocytes have decreased expression of
genes involved in mitochondriogenesis and lipid metabolism, and
increased expression of pro-inﬂammatory markers [69]. Surprisingly,
expression of adiponectin and leptin is nearly absent in these cells. This
unique molecular phenotype suggests that BM-derived adipocytes
may be deleterious to metabolic health, and certainly warrant fur-
ther investigation.
3.3. Potential adipocyte progenitor niches
Stem cells typically reside in specialized anatomical locations, known
as stem cell niches, where neighboring cells and cues from the microen-
vironment maintain quiescence or trigger activity [74–76]. The stem cell
niche may be compartmentalized into distinct domains that enhance
dormancy, or provide cues for proliferation and differentiation [75,77].
Asmentioned above, preadipocytes have been localized to a perivascular
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the cell types and extrinsic signals that balance quiescence and recruit-
ment of progenitors are currently unknown. It is important to note that
the vast majority of cells in AT are not mature fat cells [81,82], but rather
are a dynamic mixture of cellular and non-cellular elements, including
progenitors, resident/recruited immune cells, ﬁbroblasts, blood vessels,
lymphatic vessels, peripheral nerves, and the extracellular matrix
(ECM). While growing evidence suggests roles for these elements
in progenitor recruitment and adipocyte function, the mechanistic
details are scant. Therefore, in this section, we will provide a brief over-
view of the cell types and niche factors that may be involved in adipocyte
progenitor recruitment. We also summarize the potential contribution of
pathologic remodeling of AT to disease states.
3.3.1. Adipose tissue macrophages
Adipose tissue macrophages have been intensively investigated as a
crucial cell type that affects themetabolic and endocrine functions of AT
[83,84].Macrophages have been classiﬁed into subpopulations based on
functional phenotypes [85]. Classically-activated M1 macrophages are
associated with immune defense and pro-inﬂammatory responses,
whereas alternatively-activatedM2macrophages are involved in tissue
repair and restoration [86]. The M1/M2 classiﬁcation has been largely
established by the in vitro characterization of mouse macrophages,
and it is important to emphasize that the in vivo polarization status of
AT macrophages exists on a dynamic continuum [86,87].
Interestingly, macrophages are believed to have trophic effects on
AT development [88,89]. Depletion of macrophages [89] or ablation
of macrophage colony stimulating factor impairs adipogenesis [90].
Macrophage-conditioned medium can inhibit preadipocyte apopto-
sis and promote survival in a PDGF-dependent manner [91]. In addi-
tion, macrophages are a major source of angiogenic factors and can
indirectly mediate AT expansion [92]. However, the speciﬁc effects
of macrophages on in vivo adipocyte progenitor activation have not
been investigated.
Pro-inﬂammatory M1 macrophages accumulate in AT during obesi-
ty [93] and thereby promote insulin resistance [94]. In contrast, polari-
zation of macrophages toward alternative activation preserves insulin
sensitivity via a PPARγ-dependent mechanism [95,96]. Additionally, a
recent study found that AT M2 macrophages secrete catecholamines,
which increase catabolism and sustain thermoregulatory functions dur-
ing cold exposure [97]. Alternatively-activated macrophages may also
prevent the adverse effects of excessive free fatty acid efﬂux during
weight loss by suppressing lipolysis [98].
3.3.2. Vasculature
Mounting data suggest that angiogenesis and adipogenesis are
tightly coupled during development [25,89,99] and postnatal fat expan-
sion [92,100–102]. In vitro studies suggest that signals derived from
surrounding vascular units directly inﬂuence preadipocyte proliferation
and differentiation. For example, Hutley et al. isolated macrovascular
endothelial cells and preadipocytes from human AT, and found that
conditioned media from endothelial cell cultures promote proliferation
of preadipocytes [103], whereas ECM obtained from rat AT-derived
endothelial cell cultures enhances differentiation of preadipocytes
[104]. However, the vascular-derived signals involved remain poor-
ly characterized.
Antiangiogenic reagents have been investigated as potential anti-
obesity therapies. Pharmacological inhibition of angiogenesis reduces
fat mass in obese mouse models [101,105]. However, the consequences
of modulating angiogenic activity appear to vary based on context.
Gain of function studies show that overexpression of VEGFA improves
metabolic proﬁles and prevents tissue dysfunction during the early
phase of diet-induced obesity [102]. In contrast, reducing vascularization
in established obesitymay improvemetabolic outcomes by inducing ap-
optosis in dysfunctional adipocytes [102].3.3.3. Innervation
The sympathetic nervous system plays an important role in regulat-
ing fatty acid mobilization and blood ﬂow in AT (reviewed in [106]). In
addition, adipocyte cellularity appears to be under sympathetic neuronal
control. Chemical sympathectomy or surgical denervation increases pro-
liferation and differentiation ofWAprogenitors [107–110], whereas sen-
sory denervation has no effect [107]. Consistent with in vivo ﬁndings,
physiological concentrations of norepinephrine inhibitWA preadipocyte
proliferation in vitro [111]. In contrast,α2 adrenergic receptor activation
induces proliferation of cultured preadipocytes [112], and upregulation
of α2 adrenergic receptors may be involved in denervation-induced ad-
ipocyte hypertrophy [110].
It is well known that adrenergic stimulation triggers the prolifera-
tion and differentiation of BA in classical BA depots [113], and in vitro
studies suggest that this effect is mediated by β1-AR [114]. Interesting-
ly, selective agonists of β3-AR have no effect on progenitor recruitment
in classic BA [56]. In contrast, β3-AR agonists can increase proliferation
and differentiation of BA progenitors in gonadalWAT and, to a lesser ex-
tent, in subcutaneousWAT [56]. It seems likely that these effects are in-
directly mediated by effects on mature fat cells, since β3-AR are not
expressed by preadipocytes. A recent study has demonstrated that deﬁ-
ciency of BAT created by genetic or surgical manipulation increased
sympathetic tone in WAT and contributed to the recruitment of BA in
WAT [115]. One intriguing questionwould bewhether de novo BA gen-
eration from progenitor proliferation is involved in this compensatory
browning of WAT driven by augmented sympathetic innervation.
3.3.4. Extracellular matrix (ECM)
The extracellular matrix (ECM) is an obligatory component of the
adipose tissue stroma that provides structural support and biochemical
signals to maintain proper AT function. Importantly, physical and bio-
chemical elements of ECMcan directMSC lineage speciﬁcation, prolifer-
ation, and differentiation (reviewed in [116]). Adipocyte progenitors
play an important role in ECM remodeling during development. Nu-
merous studies have documented changes in the abundance and com-
position of ECM produced by preadipocytes during differentiation
(reviewed in [117,118]). For example, differentiating preadipocytes
rapidly upregulate expression of collagen IV and various laminin com-
plexes, which remain high throughout the differentiation [119]. On
the other hand, ﬁbronectin expression decreases during adipocyte dif-
ferentiation in vivo [120] and in vitro [121]. Together, these ﬁndings
suggest that ECM conﬁguration undergoes a transition from a ﬁbrillar
to a laminar structure to accommodate adipocyte growth and fat stor-
age [118].
ECM degrading enzymes also play a crucial role in modifying ECM
structure and creating a permissive environment for tissue growth/
remodeling. The proteolytic system includes ﬁbrinolytic enzymes
and numerous matrix metalloproteinases (MMP) that affect AT de-
velopment (reviewed in [122]). For example, genetic inactivation of
MMP3 enhances hyperplastic and hypertrophic expansion of AT during
HFD feeding [123,124]. Knockout of MMP3 also accelerates develop-
ment of mammaryWAT [125]. Inhibition of MMP2 andMMP9 by phar-
macologic reagents or neutralizing antibodies reduces preadipocyte
differentiation in vitro [126,127]. General pharmacological inhibition
of MMP activity decreases the AT mass of mice fed a HFD [128], al-
though interpretation of pharmacological inhibition studies is compli-
cated by the fact that broad-spectrum inhibitors can affect multiple
MMP subtypes and other proteolytic enzymes.
While the aforementioned in vivo and in vitro studies support in-
volvement of multiple MMPs in adipogenesis under various conditions,
MT1-MMP seems to play an especially important role. WAT develop-
ment is not adversely affected by knockout of MMP2, MMP9, or MMP3
[129]; however, ablation ofMT1-MMPproduces a lipodystrophic pheno-
type [129]. MT1-MMP is a membrane-tethered collagenase that de-
grades pericellular type 1 collagen, which is abundantly expressed in
both undifferentiated and mature AT [129]. Interestingly, MT1-MMP
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from MT1-MMP null mice readily differentiate in 2D-culture condition
upon adipogenic induction, but not when restricted by a 3D-collagen
gel scaffold. Similarly, transplanted preadipocytes lacking MT1-MMP
fail to become adipocytes in wild type recipient mice.
Dysregulation of ECM synthesis and turnover can lead to ﬁbrosis and
dysfunction of AT. Fibrosis is a common pathophysiological response to
chronic injury in which excess accumulation of ﬁbrotic ECM distorts tis-
sue architecture and impairs the function of parenchymal cells [130].
During obesity, metabolically-challenged AT increases ﬁbrous collagen
production and upregulates related genes [84,131,132]. Consequently,
increased ECM stiffness restricts adipocyte hypertrophy, and may cause
ectopic fat accumulation [131]. Deletion of collagen VI in ob/ob mice en-
hances hypertrophic expansion and improves metabolic proﬁle [131].
Adipose tissue macrophages, which are recruited in obese states, con-
tribute to ﬁbrosis by stimulating ﬁbroblast ECM synthesis [133,134]. In
addition, local hypoxia may contribute to ﬁbrosis via HIF1α dependent
mechanisms [132]. Although ECM-producing ﬁbroblasts are a keymedi-
ator of pathogenesis of ﬁbrosis, the cellular origin of adipose tissue ﬁbro-
blasts is not known.However, since PDGFRα+cells have been identiﬁed
as adipo-ﬁbrogenic progenitors in muscle [135–138], it is likely that
these cells can become ﬁbrogenic under pathological conditions.
4. Adipose tissue plasticity
Adipocytes are replenished throughout an organism's life, and are
dynamically regulated in terms of their numbers, size, and metabolic
characteristics. Adipocyte progenitors are activated during homeostatic
turnover and hyperplastic expansion, and can also participate in cata-
bolic remodeling, or “browning” of AT. Certain differentiated adipocytes
can also contribute to AT plasticity by undergoing a phenotypic switch
between anabolic and catabolic states. Here, we review recent work
that highlights the range of cellular and metabolic phenotypes that
exist in typical “white” adipose tissue depots, and points to possible
avenues for engineering beneﬁcial phenotypes in vivo.
4.1. Control of adipocyte cellularity
Adipocyte cellularity is determined early in life [139–142], yet there
is clear propensity for cell renewal throughout the lifetime. Metabolic
labeling studies with deuterium indicate that the half-life of adipocytes
in humans is about 6 months, representing a turnover rate of 60% per
year [143]. On the other hand, 14C decay analysis by Spalding et al.
found that turnover is much less, with adipocytes replaced on average
every 8.3 years. Interestingly, turnover is independent of body mass
index, further suggesting that adipocyte number is determined at an
early age and is relatively static in adulthood [141]. Despite these dis-
crepancies in estimates of adipocyte lifetime, the cells within AT clearly
turnover in the adult, and this phenomenon might be exploited for
therapeutic purposes. Prior to the 1960s, it was thought that adipocytes
were static in the rodent, but recent estimates indicate that mouse adi-
pocytes are turned over every six months, with 1–5% of adipocytes
being replaced every day [144].
Whether AT expansion occurs by adipocyte hypertrophy or hyperpla-
sia depends upon anatomic location in humans and rodents [51,145,146].
The in vitro proliferation potential of progenitors correlates with depot-
speciﬁc adipocyte hyperplasia in response to a high fat diet [51,145].
These data agree with human studies in which overfeeding increased
lower-body fat depots by hyperplasia, whereas abdominal fat in-
creased by hypertrophy [146]. Adipogenesis is thought to occur
once hypertrophied fat cells reach a critical size [147]. This process
involves adipocyte death [141] and the proliferation of progenitors,
followed by the appearance of smaller adipocytes [148]. Inherent
differences in the ability of depots to expand by proliferation might be
important in determining metabolic outcomes, considering the poor
metabolic proﬁle associatedwith excessive visceral fat in humans [149].4.2. Plasticity of adipocyte phenotype
Adipocytes within WAT depots have a remarkable capacity to alter
their metabolic phenotype from typical WA to those resembling BA
[150–152]. This phenomenon has been referred to as “browning” and
is readily induced by cold exposure and β-adrenergic stimulation [151].
Browning has been extensively demonstrated only in small mammals,
and the extent to which this occurs in humans is an open question. Typ-
ically, browning involves the appearance of multilocular adipocyte clus-
ters that are dispersed among unilocular WA [153,154]. The browning
phenomenon varies among WAT depots and is strongly inﬂuenced by
numerous genetic factors [155,156]. These multilocular, UCP1+ adipo-
cytes were initially called “convertible,” since the phenotype can be in-
duced from existing unilocular UCP1− cells without cell proliferation
[157–159]. Although recent groups have named these cells “brown in
white” (BRITE) [160] or beige [39], it is not clear whether these various
designations refer to the same cell type [56,150,160,161]. Indeed, limited
genetic tracing experiments suggest that there may be heterogeneity
among cells types that are capable of browning [56,162].
Analyses of adipocyte ultrastructure suggest that the WA/BA transi-
tion can be bidirectional [159,163]. Interestingly, those depots that are
most susceptible to browning, such as retroperitoneal and inguinal fat
pads, are densely populated with multilocular UCP1+ adipocytes
early in development, and these cells likely revert to a WA-like pheno-
type in adulthood [161,164,165]. BA in WAT can also be derived from
the recruitment of progenitors, which appears to be the major mode
of browning of the gonadal fat depot [56]. Early work from our group
established that BA in abdominal WAT can arise from new cellular pro-
liferation [150].More recently, our group utilized lineage tracing studies
to demonstrate that greater than 90% of BA in abdominal WAT arise
froma subpopulation of CD34+cells that express PDGFRα [56]. The ap-
pearance of these inducible BA is dependent upon the stimulus, as a
dose of β3-AR agonist that promotes fatty acid-induced inﬂammation
in WAT reduces their appearance [166–168]. In addition, prospective
analyses have identiﬁed progenitor cells that respond to activation of
the cyclooxygenase 2/prostaglandin pathway [16] and give rise to BA
both in vitro and in vivo [160,162].
While some BA-like adipocytes express UCP1 [153,163], UCP1 is not
essential for the chronic thermogenic actions of β3-AR agonists, or for
the appearance of multilocular fat cells in white fat depots [163,169].
These BA-like cells, which are found mostly in abdominal (gonadal)
fat pads, are multilocular and have abundant mitochondria, yet clearly
lack UCP1 [163]. UCP1−multilocular adipocytes exhibit elevated met-
abolic rate [170] and PPARα-dependent upregulation of fatty acid oxi-
dation [166].
5. Pathological remodeling of adipose tissue
Substantial evidence suggests that adverse consequences of obesity
have their origins in the pathological remodeling of AT [84]. Numerous
studies demonstrate that obesity in mice and man is associated with
elevated expression of inﬂammatory cytokines, adipocyte death, and
recruitment of inﬂammatory macrophages [171–174]. Importantly,
genetic and/or pharmacological approaches that reduce AT inﬂamma-
tion restore anabolic functions and improve systemic insulin action
[171,175]. Here we brieﬂy summarize mechanisms of inﬂammation
in obesity; recent reviews have covered this topic in greater depth
[176,177].
Chronic overnutrition increases the occurrence of hypertrophic fat
cells, which upon reaching a critical size become distressed and under-
go necrosis/apoptosis. Adipocyte cell death recruits macrophages,
which surround and ultimately remove the dead fat cells [174]. These
adipocyte clearance structures are often called “crown-like structures”
(CLS) which describe their appearance in histological sections. The for-
mation of these CLS further triggers a local inﬂammatory response that
impairs the functioning of nearby adipocytes [178,179]. Inﬂammation
Fig. 1. Adipocyte receptors that have been proposed to promote the browning of white fat
or maintenance of a brown adipocyte (BA) phenotype. β3-Adrenergic receptor (β3-AR)
which signals through protein kinase A (PKA) to phosphorylate (P) and activate transcrip-
tion factors such as cAMP response element binding protein (CREB). β3-ARs also activate
p38 which phosphorylates ATF2 to promote the transcription of genes such as PGC1α
and UCP1. In parallel, β3-ARs stimulate lipolysis by adipose triglyceride lipase (ATGL) and
hormone sensitive lipase (HSL). Free fatty acids (FFA) mobilized by these lipases activate
peroxisome proliferator-activated receptor (PPARα) and PPARδ (not shown) to promote
the expression of BA genes. Natriuretic peptides (NP) bind natriuretic peptide receptors
(NPR) and activate protein kinase G (PKG). In addition, bone morphogenetic protein
(BMP8b) and BMP7 signal through p38 by unknownmechanisms (dashed line). Fibroblast
growth factor 21 (FGF21) produced by the liver and in brown adipose tissue, acts through
the receptor FGF1 and scaffold βKlotho to activate ERK1/2 and promote a BA phenotype
through unknown pathways. Transient receptor potential cation channel subfamily M
member 8 (TRPM8), which is activated by menthol, promotes thermogenesis in BAT in a
PKA-dependent manner. Thiazolidinediones (TZDs) activate PPARγ, which through
PRDM16 and the deacetylase sirtuin1 (SirT1), promote the browning of white fat. Finally,
the hormone irisin, secreted from muscle, binds a yet unknown receptor to promote the
appearance of BA by signaling through a PPARα dependent pathway.
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contributes to the production of lipid mediators that impair insulin sig-
naling [180]. In addition, AT ﬁbrosis promotes inﬂammatory responses
and exacerbates insulin resistance in fat tissue [132]. Notably, reducing
the constraints of the ECM increases fat cell expansion and improves
whole body metabolism [131]. In humans with obesity, the exhaustion
[181] and impaired commitment of adipocyte progenitors [182,183]
may also limit beneﬁcial AT expansion.
Aging is associated with deleterious alterations in AT. Preadipocytes
from aged rats [184] and older individuals [185] have reduced ability to
proliferate and differentiate. The diminished ability of aged progenitors
to replicate might be due to cellular senescence, which can be observed
in vitro [186] and in vivo [187,188]. Importantly, genetic approaches
that reduce senescence improve insulin sensitivity [187], and removal
of senescent cells improves age-related loss of AT [188]. Aging in mice
is also associated with reduced adrenergic tone and loss of brown adi-
pocytes in subcutaneous WAT [189].
6. Therapeutic remodeling of adipose tissue
As mentioned in the Introduction, one means of addressing the ad-
verse metabolic consequences of obesity is to increase the capacity of
AT to buffer excess energy. PPARγ is themaster regulator of adipogenesis,
and its activation with thiazolidinediones (TZDs) induces metabolic and
cellular remodeling that improves the ability of AT to sequester fatty
acids. On the other hand, β3-AR agonists improve metabolism in rodent
models of type 2 diabetes by expanding the ability of brown and white
adipose tissues to oxidize fatty acids in situ, and thereby prevent systemic
lipotoxicity. Although β3-AR agonists have not been successful in
humans [190], their experimental use in rodent models has provided
new information on the mechanisms of AT plasticity. This new apprecia-
tion of AT plasticity has sparked an explosion of work that is likely to lead
to new means of expanding beneﬁcial phenotypes in vivo.
6.1. Peroxisome proliferator-activated receptor γ
PPARγ is a nuclear receptor that is highly expressed in AT [191] and
is a master regulator of adipogenesis [192] (reviewed in [193]). PPARγ
is selectively activated by a class of anti-diabetic agents, the TZDs
[193]. In humans, TZDs ameliorate insulin resistance, increase peripher-
al glucose utilization and improve serum lipid levels [194]. The thera-
peutic actions of TZDs in rodents are mediated by several molecular
targets in multiple tissues [195–197]; nonetheless, activation of the AT
PPARγ appears to play a central role [198,199]. TZDs improve the ability
of AT to sequester excess energy by upregulating the expression of
genes involved in de novo lipogenesis and fatty acid uptake [200].
TZDs promote fat storage preferentially in subcutaneous WAT without
increasingwhole body energy expenditure [201]. TZDs also improve in-
sulin sensitivity by improving adipokine proﬁles [202]. Adiponectin
levels are reduced in obesity [203] and are correlated with insulin sen-
sitivity [202]. TZD treatment rapidly increases adiponectin levels [204],
and in mice, these effects involve activation of AMP kinase by
adiponectin [205]. TZDs also activate PPARγ in certain lipid-sensing reg-
ulatory T-cells that regulate the inﬂammatory state of AT [195]. Similar-
ly, TZDs suppress the expression of pro-inﬂammatory genes [206,207]
and promote the recruitment of anti-inﬂammatory tissue-remodeling
macrophages [208]. Consistent with an adipocentric view, transgenic
overexpression of PPARγ in AT mimics the systemic delivery of TZDs
by reducing inﬂammation and improving adipokine proﬁles [199]. In
addition, new work demonstrates that the crosstalk between PPARγ
and the growth factors FGF1 and FGF21 is critical for the actions of
TZDs in maintaining healthy AT [209,210].
TZDs might impart therapeutic effects by increasing catabolic
functions of WAT (Fig. 1). TZDs promote fatty acid re-esteriﬁcation
and futile cycling [211], which are energetically-demanding process-
es that increase mitochondrial biogenesis, energy expenditure, andfatty acid oxidation [212]. The clinical responsiveness of diabetic pa-
tients to TZDs is correlatedwith improvements inmitochondrial gene ex-
pression and reductions in inﬂammation [213]. In vitro, PPARγ agonism
promotes the appearance of UCP1+ brown adipocytes in a population
of EWAT-derived progenitors [160]. The mechanisms by which PPARγ
agonism facilitates the appearance of brown adipocytes include stabiliza-
tion of PRDM16 [214], suppression of WA-speciﬁc genes [215], and
SirT1-dependent deacetylation of PPARγ [216]. Interestingly, the binding
of PPARγ to genes that determine brown or white adipocyte expression
patterns is depot-dependent, suggesting that the ability of TZDs to pro-
mote a brown or white phenotype is epigenetically pre-programmed
[217]. Whether TZDs promote recruitment and activation of brown adi-
pocytes in humans is not known; however, PPARγ agonism promotes
characteristics of brown adipocytes in a human pre-adipocyte cell line
[218].
6.2. β3-Adrenergic receptors
In rodents, physiological or pharmacological stimulation of β3-ARs
rapidly activates nonshivering thermogenesis in brown fat [219]. Al-
though the thermogenic actions of β3-AR agonists have been attributed
to activation of brown fat, activation of both BAT andWAT is required for
a full thermogenic response [154]. The anti-diabetic effects of β3-AR ag-
onists require chronic treatment [219], and are correlatedwith dramatic
remodeling of WAT [150,220]. Interestingly, improvement in insulin
sensitivity can be seen prior to changes in body weight [221].
The mechanisms bywhich β-ARs enhance the catabolic character of
brown fat and the appearance of BA in WAT are not completely under-
stood, but are complex and involve synergy among various signaling
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the browning of white fat, such as activation of p38 [223] and cAMP
response element-binding protein [224], likely lie downstream of the
cAMP/protein kinase A signaling pathway [156]. One critical factor
that is upregulated by PKA is PGC1α, transcriptional co-activator of nu-
clear receptors that is necessary for themaximal induction ofmitochon-
drial biogenesis and UCP1 expression [225–227]. In addition, PPARα
and type 2 diodinase have been identiﬁed as genes associated with
maximal induction of UCP1 expression in WAT depots [228].
In addition to the direct activation of transcription factors, PKA also
triggers lipolysis, which provides ligands for the nuclear receptors
PPARα and PPARδ. Dynamic imaging shows that ligands for PPARα and
PPARδ are produced within minutes of activating lipolysis and function
tomatch theoxidative capacitywith the supply of fatty acids [229].More-
over, knockout of hormone sensitive lipase or PPARα delays induction of
genes involved in mitochondrial biogenesis and fatty acid oxidation dur-
ing β3-AR agonist treatment [220,230]. Similarly, overexpression of adi-
pose triglyceride lipase (ATGL) enhances the catabolic phenotype of
white fat, while AT-speciﬁc deletion of ATGL promotes awhite fat pheno-
type in BAT, with reduced expression of PPARα target genes [231].While
these data indicate that intracellular lipolysis supports a catabolic pheno-
type, excessive mobilization of fatty acids can trigger inﬂammation in
WAT [98,150,167,220,230].
6.3. Other factors that promote a BA phenotype
The role ofβ-ARs in browning ofWAThas been known for some time,
but recent evidence demonstrates that the appearance of BA andmainte-
nance of a BAprogramcanbe induced by other hormones, cytokines, and
growth factors (Fig. 1). Bostrom et al. demonstrated that a muscle-
derived cytokine, irisin, is increased by exercise and induces the brow-
ning of subcutaneous AT [232]. Interestingly, the induction of BA genes
by irisin involves activation of PPARα; however,whether irisin has a sim-
ilar role of improving metabolic outcomes in humans is a matter of de-
bate [233,234]. BMP7, a morphogen important for development, can
promote the differentiation of a population of preadipocytes toward BA
and is necessary for the formation of BAT,while overexpression increases
energy expenditure [162]. BMP7 also increases mitochondrial activity in
mature brown adipocytes [235]. Additionally, BMP8b acts directly on
brown fat and via the central nervous system to increase thermogenic
activity [236]. Fibroblast growth factor 21 (FGF21) has been suggested
to drive BAT-dependent thermogenesis after birth [237] and contribute
to browning of white fat in adults [238,239]. The metabolic effects
of FGF21 require signaling through FGFR1 and the scaffold βKlotho
[240–242]. Interestingly, cold-induced elevation of circulating FGF21
levels is associated with thermogenesis in humans [243]. In addition,
transient receptor potential cation channel subfamily M member 8
(TRPM8), the cold-sensing receptor that is activated by menthol, is
expressed in BAT and promotes UCP1-dependent thermogenesis [244].
The browning ofWAT can also be induced in transgenic animals that ex-
press transcription factors such as PRDM16 [245], RIP140 [246], pRB and
p107 [247], and FoxC2 [248]. Finally, cardiac-derived natriuretic peptides
(NP) [249], which are potent activators of lipolysis in human fat cells, can
promote the browning ofwhite fat and thermogenesis inmice, and drive
increased respiration in human fat cell cultures [250]. Importantly, NP
treatment stimulates lipolysis and increases lipid oxidation and energy
expenditure in humans [249,251]. An important question to address is
whether natriuretic peptides enhance energy expenditure by acting on
brown fat, skeletal muscle, or both [252].
7. Concluding remarks
The mechanistic study of cellular and metabolic plasticity of AT will
raise newopportunities in treating obesity and its relatedmetabolic dis-
orders. Understanding the signals that determine progenitor fate may
lead to new therapeutic approaches. For example, PDGFRα progenitorsinWAT appear to be capable of differentiating intoWA, BA, or ﬁbroblasts.
Clearly, understanding the cues that drive the fate of this population could
be key to preserving metabolically healthy WAT. Interestingly, recent
evidence suggests that TZD-enhanced insulin sensitization is associated
with the appearance of new adipocytes in muscle [213]. Thus, an under-
standing of how TZDs target speciﬁc progenitor populations is also
important.
The metabolic improvements associated with activation of BAT in
rodents have led to the suggestion that human BAT (hBAT) might be
developed as a therapeutic target. Agonists of β3-ARs have potent
anti-obesity and anti-diabetes effects in rodent models [219,253].
However, β3-AR expression is low in human AT, and selective
β3-AR agonists have not been proven effective in man [190]. Thus
far, indirect (ephedrine) and direct (isoproterenol) sympathomi-
metics have also failed to activate hBAT at doses that raise the meta-
bolic rate [254–256]. Clearly, additional means other than cold stress
will be needed for BAT activation to be a practical target in humans.
Since fatty acids are necessary and sufﬁcient to drive brown fat ther-
mogenesis [257], promoting lipolysis [229,231,258] by mechanisms
that are parallel or distal to adrenergic receptors may be effective.
Whether the reported amounts of BAT in humans are sufﬁcient to have
an effect on whole energy expenditure is a matter of debate. Direct mea-
sures of bloodﬂowandO2metabolism in hBAT during cold stress indicate
that the amount of activity of human BAT would need to increase by ap-
proximately 50 times to impact energy balance [259]. Increasing the
amount of BAT or BA in WAT could be accomplished by manipulating
transcription factors such as PRDM16 or Rb/p107; however, the critical
roles of these factors in organogenesis and transformation will need to
be considered [260,261]. Targeting microRNA (miRNA) that modulates
brown fat differentiation [262,263] or browning of white fat [264] is an
additional possibility. Others have suggested that fat transplants [265],
and inducible pluripotent stem cells [266,267] could be used to expand
brownAT in vivo.However, BAT is not simply a single cell type, but a com-
plex organ that requires a vasculature to supply oxygen and energy to be
burned and a means of thermogenic activation. Future studies are re-
quired to address these hurdles; however, given recent advances in
knowledge, targeting adipose tissue plasticity seems to be an increasingly
feasible avenue for therapeutic intervention.
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